Artivion, Inc. (NYSE:AORT) Stock Position Decreased by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its position in Artivion, Inc. (NYSE:AORT) by 8.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 194,630 shares of the company’s stock after selling 17,094 shares during the quarter. Principal Financial Group Inc.’s holdings in Artivion were worth $5,181,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC bought a new position in Artivion during the third quarter valued at about $5,798,000. Franklin Resources Inc. lifted its holdings in Artivion by 14.4% in the 3rd quarter. Franklin Resources Inc. now owns 21,107 shares of the company’s stock worth $553,000 after purchasing an additional 2,663 shares during the last quarter. Tidal Investments LLC boosted its position in Artivion by 602.2% during the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock worth $4,179,000 after purchasing an additional 134,642 shares during the period. Barclays PLC grew its holdings in Artivion by 346.3% during the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after purchasing an additional 54,996 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Artivion by 69.1% in the third quarter. Jane Street Group LLC now owns 61,035 shares of the company’s stock valued at $1,625,000 after purchasing an additional 24,945 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Trading Down 1.8 %

Artivion stock opened at $28.08 on Friday. The business has a 50 day moving average price of $28.32 and a two-hundred day moving average price of $26.69. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 12 month low of $16.48 and a 12 month high of $30.45. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -1,404.00 and a beta of 1.75.

Insider Activity

In related news, SVP Jean F. Holloway sold 8,070 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total value of $243,068.40. Following the completion of the transaction, the senior vice president now owns 153,862 shares of the company’s stock, valued at $4,634,323.44. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Andrew M. Green sold 7,618 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total transaction of $228,540.00. Following the transaction, the vice president now owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. This represents a 18.53 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 20,017 shares of company stock worth $600,007. Company insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

AORT has been the topic of a number of research analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research note on Tuesday, December 10th. Stifel Nicolaus raised their price target on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 13th. Oppenheimer boosted their price objective on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 target price on shares of Artivion in a report on Monday, December 9th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $31.80.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.